Daniela de Totero
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Background/Objectives: Three-dimensional (3D) in vitro cell culture models have recently stimulated great interest since they may have more pre-clinical value than conventional in vitro 2D models. In fact, 3D culture models may mimic the in vivo biophysical 3D structure of tumors and cell-to-cell interaction, thereby representing a more useful approach to testing drug responses. In this study we have developed a 3D culture model of an EBV+/CD30+cell line, D430B, previously characterized as an Anaplastic Large Cell Lymphoma of B phenotype (B-ALCL), to determine the cytotoxic activity of the antibody–drug conjugate Brentuximab Vedotin. Methods: By using of ultra-low attachment plates, we developed D430B spheroids that appeared particularly homogenous in terms of growth and size. Results: Brentuximab Vedotin treatment (1 to 20 μg/mL) turned out to be significantly cytotoxic to these cells, while the addition of the anti-CD20 chimeric antibody Rituximab (10 μg/mL) appeared almost ineffective, even though these cells express CD20. Moreover, when we co-cultured D430B cells with stromal cells (HS5), to re-create a microenvironment representative of neoplastic cell/mesenchymal cell interactions within the lymph node, we observed a significant, although faint, protective effect. Conclusions: This simple and reproducible method of generating D430B-ALCL spheroids to evaluate their response to Brentuximab Vedotin treatment, as here described, may provide a valuable preliminary tool for the future pre-clinical screening of patients’ primary lymphoma cells or the development of novel therapies for this type of pathology and related diseases.
Year:
2025
Background: Bronchoalveolar lavage (BAL) constitutes a valuable diagnostic approach for the differential diagnosis of various pulmonary fibrotic diseases. BAL fluids from patients with interstitial lung diseases (ILDs) can also be utilized for research purposes, offering cell populations suitable for functional and phenotypical studies. In this study, we demonstrate the feasibility of isolating a discrete number of fibroblasts/myofibroblasts in vitro from the BAL fluid from ILD patients, a procedure typically performed during the early stages of disease when high-resolution computed tomography does not yield a definitive diagnosis. Methods: We obtained BAL samples from a total of 43 patients. Fibroblasts were successfully derived in vitro from 20 patients, with larger quantities of cells from 11 patients. Whenever possible, the cells were cultured and expanded until passage 12–15. Fibroblasts could be expanded to passage 36 in only one case. The expression of typical fibrotic markers, such as type I collagen, α-smooth muscle actin, and fibronectin-extra domain A or B (FN-EDA/-EDB), was therefore compared in fibroblasts obtained from ILD-patients with fibroblasts derived from non-diseased controls by quantitative RT-PCR, immunofluorescence, and cytofluorographic analysis. The rate of proliferation, migration, and response to the anti-fibrotic drug pirfenidone was further determined in 2D and in 3D models of in vitro cultures. Results: A specific morphological heterogeneity among fibroblasts/myofibroblasts derived from patients with fibrotic or non-fibrotic ILD was observed, such as enlarged and flattened shaped cells vs spindle-shaped cells. Moreover, a higher expression of α-smooth muscle actin (α-SMA), type I collagen (collagen I), and fibronectin was demonstrated in ILD fibroblasts than in control fibroblasts. The anti-fibrotic drug pirfenidone was effective in inhibiting the growth and migration of ILD-fibroblasts both in 2D and 3D in vitro models. Conclusions: Collectively, the present study suggests that BAL-derived fibroblasts from ILD patients may serve as a useful in vitro model for studying and assaying pulmonary fibrosis. This approach has the potential to improve our understanding of ILD pathogenesis and overcome ethical and availability concerns associated with biopsy-derived tissues.
Year:
2025
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries. Although characterized by the progressive expansion and accumulation of leukemic B cells in peripheral blood, CLL cells develop in protective niches mainly located within lymph nodes and bone marrow. Multiple interactions between CLL and microenvironmental cells may favor the expansion of a B cell clone, further driving immune cells toward an immunosuppressive phenotype. Here, we summarize the current understanding of bone tissue alterations in CLL patients, further addressing and suggesting how the multiple interactions between CLL cells and osteoblasts/osteoclasts can be involved in these processes. Recent findings proposing the disruption of the endosteal niche by the expansion of a leukemic B cell clone appear to be a novel field of research to be deeply investigated and potentially relevant to provide new therapeutic approaches.
Year:
2023
Collaborators (2)
Marco Musso
Ricercatore sanitario
Ospedale Policlinico San Martino
Mauro Krampera
Docenti di ruolo di Ia fascia
University of Verona
Make your next move.
Prepare your application
Review drafts before you send them.